Of these, the so-called ‘triple-negative breast carcinoma’ (TNBC) marked by the absence of estrogen receptor (ER) and progesterone receptor (PgR) expression, as well as the lack of human epidermal growth factor receptor 2 (HER2) protein overexpression. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.